Diagnostic test maker Gen-Probe Inc. said Thursday its second-quarter net income jumped 42 percent on higher revenue from blood screening and women’s health products.

The company earned $28.1 million, or 57 cents per share, up from $19.8 million, or 38 cents per share, during the same period a year prior. Revenue rose 15 percent to $138.6 million from $120.5 million.

Excluding one-time gains and charges, the company said it earned 52 cents per share. Analysts polled by Thomson Reuters expected net income of 49 cents per share on $137 million in revenue.

Clinical diagnostics revenue rose 10 percent to $73.9 million, while blood screening revenue rose 20 percent to $55.7 million. Research product and services revenue fell 8 percent to $3.2 million, while collaborative research revenue was $4.1 million and royalty revenue was $1.8 million.

Looking ahead, the company said it expects adjusted net income in 2010 between $2.12 and $2.25 per share on revenue between $545 million and $562 million. Analysts expect net income of $2.18 per share on revenue of $558.6 million.

Shares of Gen-Probe rose $2.12, or 5 percent, to $44.50 in after-hours trading after falling 92 cents to close at $42.38 during the regular trading session.